Announcements Trials

Browse Landscape

Phase

Status

Completed 3 Active not recruiting 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 52 Brain Neoplasms 28 Glioma 22 Gliosarcoma 19 Melanoma 18 Astrocytoma 17 Central Nervous System Neoplasms 11 Oligodendroglioma 10 Neoplasms 9 Neoplasm Metastasis 8 Recurrence 6 Carcinoma, Non-Small-Cell Lung 5 Neuroblastoma 4 Lymphoma 4 Ependymoma 4 Diffuse Intrinsic Pontine Glioma 3 Breast Neoplasms 3 Sarcoma, Ewing 2 Neurologic Manifestations 2 Neuroectodermal Tumors, Primitive 2 Neoplasms, Second Primary 2 Meningeal Carcinomatosis 2 Medulloblastoma 2 Bone Neoplasms 2 Urinary Bladder Neoplasms 1 Thrombocytopenia 1 Tetanus 1 Spinal Cord Neoplasms 1 Solid Tumors 1 Small Cell Lung Cancer Recurrent 1

Interventions

iadademstat 1 Temozolomide 1 Sunitinib 1 Paclitaxel 1 PE regimen 1 Irinotecan 1 Fluorouracil 1 Everolimus 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Carcinoma, Neuroendocrine × Temozolomide × Clear all

NCT03387592 2025-03-10

SENECA

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Terminated

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡